SCHEMBL13720973

SCHEMBL13720973

COC(=O)CN(C(=O)Oc1ccc(OC)cc1)[C@@H](C)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
PPARG P37231 2/20 0.40
PPARA Q07869 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.40
CYP3A4 P08684 1/20 0.40
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ESR2 Q92731 2/20 0.37
LTA4H P09960 1/20 0.37
GAA P10253 2/20 0.37
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FAAH O00519 1/20 0.36
CALM1 P0DP23 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14281847 0.90 HIF1A (0.41) ALOX5PPARGPPARAKMT2AMEN1
SCHEMBL13721907 0.89 ALOX15 (0.42) ALOX5PPARGPPARAKMT2AMEN1
SCHEMBL13721776 0.89 ALOX15 (0.42) ALOX5PPARGPPARAKMT2AMEN1
SCHEMBL4907904 0.88 PPARG (0.45) PPARGPPARAKMT2AMEN1MAPT
SCHEMBL4907903 0.88 PPARG (0.45) PPARGPPARAKMT2AMEN1MAPT
SCHEMBL13899504 0.86 ALDH1A1 (0.37) PPARGKMT2AMEN1MAPTCYP3A4
SCHEMBL13899564 0.86 PPARG (0.47) PPARGPPARAKMT2AMEN1MAPT
SCHEMBL13899524 0.86 ALDH1A1 (0.37) PPARGKMT2AMEN1MAPTCYP3A4
SCHEMBL13899483 0.86 MEN1 (0.47) ALOX5PPARGKMT2AMEN1MAPT
SCHEMBL10184611 0.85 ESR1 (0.41) PPARGPPARAMAPTRAB9AESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-7507757-B2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-24 US disclosed
US-7507757-B2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-24 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA ALOX5 1124/4885PPARG 65/4885PPARA 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.